Assay for detecting closely-related serotypes of human papillomavirus (HPV)

Patent metadata

Field	Value
Publication number	US-9868997-B2
Application number	US-201414179113-A
Country	US
Kind code	B2
Filing date	Feb 12, 2014
Priority date	Feb 16, 2010
Publication date	Jan 16, 2018
Grant date	Jan 16, 2018

Abstract

A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected.

First claim

The invention claimed is:

1. A multiplex assay for detecting the presence or absence of at least one serotype of human papillomavirus (HPV) in a biological sample wherein signals from more than one serotype are on a single channel, comprising:
providing a biological sample;
contacting the biological sample with at least three oligonucleotide primer/probe sets, each of which comprises at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50 and at least two oligonucleotide primers each of which has a nucleotide sequence length of about 10 to about 150 under conditions such that the probes and primers anneal to a target sequence and wherein each primer/probe set is at least preferential for a specific serotype of an organism wherein the first and second primer/probe sets are degenerate with respect to each other and wherein the degenerate probes each are modified by a signal moiety that emits signal that is detectable on the same channel and wherein the third primer/probe set is not degenerate with respect to the other two primer/probe sets and discriminates for a third serotype that is not the serotypes to which the degenerate primer/probe sets preferentially anneal and wherein the probe in the third primer/probe set is modified by a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate probes wherein the target for the degenerate primer/probe set is SEQ ID NO: 37 wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the third primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 70% homologous to at least one of SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 33 and does not discriminate for HPV 33 serotype with respect to HPV serotype 58, wherein the first primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 7, 9, 11, 13, 15 and sequences that are at least 70% homologous to SEQ ID NOS: 7, 9, 11, 13, and 15; and the second primer/probe set selects for HPV serotype 58 and does not discriminate for HPV 58 serotype with respect to HPV serotype 33, wherein the second primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 8, 10, 12, 14, 16 and sequences that are at least 70% homologous to SEQ ID NOS: 8, 10, 12, 14, and 16;
amplifying, if present, the target sequence; and
monitoring for detection the label as an indication of the hybridization of the probe set to the target sequence thereby indicating the presence or absence of at least one of the serotypes of HPV.

2. The assay of claim 1 further comprising contacting the biological sample with at least one additional degenerate primer/probe set wherein the target for the additional degenerate primer/probe set is selected from the group consisting of SEQ ID NOS: 36 and 38.

3. The assay of claim 2 wherein the additional primer/probe set target is SEQ ID NO: 36 and wherein the third primer/probe set is configured to discriminate for HPV serotype 51 and is not degenerate with respect to the first or second primer/probe set, wherein the third primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 24-29 and sequences that are at least 70% homologous to at least one of SEQ ID NOS: 24-29; the first primer/probe set selects for HPV serotype 39 and does not discriminate for HPV 39 serotype with respect to HPV serotype 68, wherein the first primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 1, 3 and 5 and sequences that are at least 70% homologous to SEQ ID NOS: 1, 3 and 5 and the second primer/probe set selects for HPV serotype 68 and does not discriminate for HPV 68 serotype with respect to HPV serotype 39, wherein the second primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6 and sequences that are at least 70% homologous to SEQ ID NOS: 2, 4 and 6.

4. The assay of claim 2 wherein the additional degenerate primer/probe set target is SEQ ID NO: 38 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the third primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 70% homologous to at least one of SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 56 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the first primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 17, 19, 21 and sequences that are at least 70% homologous to SEQ ID NOS: 17, 19,and 21 and the second primer/probe set selects for HPV serotype 66 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the second primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 18, 20, 22, 23 and sequences that are at least 70% homologous to SEQ ID NOS: 18, 20, 22, and 23.

5. The assay of claim 3 wherein the third primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 24-29 and sequences that are at least 80% homologous to SEQ ID NOS: 24-29; wherein the first primer/probe set comprises at least one of the sequences selected from the group consisting of SEQ ID NOS: 1, 3 5 and sequences that are at least 80% homologous to SEQ ID NOS: 1, 3 and 5; and the second primer/probe set comprises at least one oligonucleotide selected from the group consisting of SEQ ID NOS: 2, 4, 6 and sequences that are at least 80% homologous to SEQ ID NOS: 2, 4 and 6.

6. The assay of claim 1 wherein the first primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 80% homologous to SEQ ID NOS: 30-35; the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 7, 9, 11, 13, 15 and sequences that are at least 80% homologous to SEQ ID NOS: 7, 9, 11, 13, and 15; and the second primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 8, 10, 12, 14, 16 and sequences that are at least 80% homologous to SEQ ID NOS: 8, 10, 12, 14, and 16.

7. The assay of claim 4 wherein the third primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 80% homologous to SEQ ID NOS: 30-35; wherein the first primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 17, 19, 21 and sequences that are at least 80% homologous to SEQ ID NOS: 17, 19 and 21; and the second primer/probe set comprises at least one oligonucleotide having a sequence selected from the group consisting of SEQ ID NOS: 18, 20, 22, 23 and sequences that are at least 80% homologous to SEQ ID NOS: 18, 20, 22, and 23.

8. The assay of claim 3 wherein the third primer/probe set comprises at least one oligonucleotide having

Assignees

• Becton Dickinson Co

Inventors

• Chen Chi
• Peck Hugh J
• Porter Michael
• Richart Gregory A
• Mcmillian Ray A

Classifications

• C12Q1/708 Primary

  for papilloma · CPC title